Does the media prefer JNJ or EBS?

In the previous week, Johnson & Johnson had 67 more articles in the media than Emergent Biosolutions. MarketBeat recorded 70 mentions for Johnson & Johnson and 3 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.04 beat Emergent Biosolutions' score of 0.24 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 47 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Positive Emergent Biosolutions 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NVAX or EBS?

In the previous week, Novavax had 6 more articles in the media than Emergent Biosolutions. MarketBeat recorded 9 mentions for Novavax and 3 mentions for Emergent Biosolutions. Emergent Biosolutions' average media sentiment score of 0.24 beat Novavax's score of -0.07 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Emergent Biosolutions 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ZBIO or EBS?

In the previous week, Zenas BioPharma had 1 more articles in the media than Emergent Biosolutions. MarketBeat recorded 4 mentions for Zenas BioPharma and 3 mentions for Emergent Biosolutions. Zenas BioPharma's average media sentiment score of 0.75 beat Emergent Biosolutions' score of 0.24 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Emergent Biosolutions 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EBS or MNKD?

In the previous week, MannKind had 2 more articles in the media than Emergent Biosolutions. MarketBeat recorded 5 mentions for MannKind and 3 mentions for Emergent Biosolutions. MannKind's average media sentiment score of 0.30 beat Emergent Biosolutions' score of 0.24 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer OPK or EBS?

In the previous week, OPKO Health and OPKO Health both had 3 articles in the media. OPKO Health's average media sentiment score of 0.69 beat Emergent Biosolutions' score of 0.24 indicating that OPKO Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Emergent Biosolutions 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Emergent Biosolutions (EBS) Competitors

$8.45 -0.08 (-0.94%)

Closing price 06/29/2026 03:59 PM Eastern

Extended Trading

$8.41 -0.04 (-0.52%)

As of 07:31 AM Eastern

Compare

EBS vs. JNJ, NVAX, ZBIO, MNKD, and OPK

Should you buy Emergent Biosolutions stock or one of its competitors? MarketBeat compares Emergent Biosolutions with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Emergent Biosolutions include Johnson & Johnson (JNJ), Novavax (NVAX), Zenas BioPharma (ZBIO), MannKind (MNKD), and OPKO Health (OPK). These companies are all part of the "medical" sector.

How does Emergent Biosolutions compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Emergent Biosolutions (NYSE:EBS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Johnson & Johnson had 67 more articles in the media than Emergent Biosolutions. MarketBeat recorded 70 mentions for Johnson & Johnson and 3 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.04 beat Emergent Biosolutions' score of 0.24 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	47 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Positive
Emergent Biosolutions	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Johnson & Johnson has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.33, suggesting that its stock price is 133% more volatile than the broader market.

Johnson & Johnson has a net margin of 21.83% compared to Emergent Biosolutions' net margin of -1.27%. Johnson & Johnson's return on equity of 32.60% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.83%	32.60%	13.29%
Emergent Biosolutions	-1.27%	10.76%	4.22%

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.60	$26.80B	$8.65	29.85
Emergent Biosolutions	$742.90M	0.59	$52.60M	-$0.28	N/A

Johnson & Johnson currently has a consensus price target of $256.70, suggesting a potential downside of 0.60%. Emergent Biosolutions has a consensus price target of $12.00, suggesting a potential upside of 42.01%. Given Emergent Biosolutions' higher probable upside, analysts clearly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Johnson & Johnson beats Emergent Biosolutions on 12 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to Novavax?

Novavax (NASDAQ:NVAX) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Novavax has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.37	$440.30M	-$0.58	N/A
Emergent Biosolutions	$742.90M	0.59	$52.60M	-$0.28	N/A

Novavax has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.33, indicating that its stock price is 133% more volatile than the broader market.

In the previous week, Novavax had 6 more articles in the media than Emergent Biosolutions. MarketBeat recorded 9 mentions for Novavax and 3 mentions for Emergent Biosolutions. Emergent Biosolutions' average media sentiment score of 0.24 beat Novavax's score of -0.07 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Emergent Biosolutions	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

53.0% of Novavax shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Emergent Biosolutions has a net margin of -1.27% compared to Novavax's net margin of -14.73%. Emergent Biosolutions' return on equity of 10.76% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Emergent Biosolutions	-1.27%	10.76%	4.22%

Novavax currently has a consensus target price of $13.00, suggesting a potential upside of 38.89%. Emergent Biosolutions has a consensus target price of $12.00, suggesting a potential upside of 42.01%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, analysts clearly believe Emergent Biosolutions is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Emergent Biosolutions beats Novavax on 9 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Zenas BioPharma had 1 more articles in the media than Emergent Biosolutions. MarketBeat recorded 4 mentions for Zenas BioPharma and 3 mentions for Emergent Biosolutions. Zenas BioPharma's average media sentiment score of 0.75 beat Emergent Biosolutions' score of 0.24 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Emergent Biosolutions	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zenas BioPharma has a beta of -0.71, meaning that its stock price is 171% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.33, meaning that its stock price is 133% more volatile than the broader market.

Zenas BioPharma has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -1.27%. Emergent Biosolutions' return on equity of 10.76% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Emergent Biosolutions	-1.27%	10.76%	4.22%

Zenas BioPharma presently has a consensus target price of $44.29, suggesting a potential upside of 73.33%. Emergent Biosolutions has a consensus target price of $12.00, suggesting a potential upside of 42.01%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Zenas BioPharma is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

78.4% of Emergent Biosolutions shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Emergent Biosolutions has higher revenue and earnings than Zenas BioPharma. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	161.30	-$377.74M	-$8.47	N/A
Emergent Biosolutions	$742.90M	0.59	$52.60M	-$0.28	N/A

Summary

Zenas BioPharma beats Emergent Biosolutions on 9 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to MannKind?

Emergent Biosolutions (NYSE:EBS) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

In the previous week, MannKind had 2 more articles in the media than Emergent Biosolutions. MarketBeat recorded 5 mentions for MannKind and 3 mentions for Emergent Biosolutions. MannKind's average media sentiment score of 0.30 beat Emergent Biosolutions' score of 0.24 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Emergent Biosolutions has a net margin of -1.27% compared to MannKind's net margin of -6.63%. Emergent Biosolutions' return on equity of 10.76% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-1.27%	10.76%	4.22%
MannKind	-6.63%	-11.21%	-3.92%

Emergent Biosolutions has a beta of 2.33, meaning that its stock price is 133% more volatile than the broader market. Comparatively, MannKind has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Emergent Biosolutions presently has a consensus price target of $12.00, indicating a potential upside of 42.01%. MannKind has a consensus price target of $8.97, indicating a potential upside of 111.53%. Given MannKind's stronger consensus rating and higher probable upside, analysts plainly believe MannKind is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by insiders. Comparatively, 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Emergent Biosolutions has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.59	$52.60M	-$0.28	N/A
MannKind	$348.97M	3.75	$5.86M	-$0.07	N/A

Summary

Emergent Biosolutions beats MannKind on 9 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Emergent Biosolutions has a net margin of -1.27% compared to OPKO Health's net margin of -36.63%. Emergent Biosolutions' return on equity of 10.76% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Emergent Biosolutions	-1.27%	10.76%	4.22%

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Emergent Biosolutions has higher revenue and earnings than OPKO Health. Emergent Biosolutions is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.88	-$225.68M	-$0.27	N/A
Emergent Biosolutions	$742.90M	0.59	$52.60M	-$0.28	N/A

OPKO Health has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.33, suggesting that its share price is 133% more volatile than the broader market.

In the previous week, OPKO Health and OPKO Health both had 3 articles in the media. OPKO Health's average media sentiment score of 0.69 beat Emergent Biosolutions' score of 0.24 indicating that OPKO Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Emergent Biosolutions	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OPKO Health currently has a consensus price target of $1.55, indicating a potential upside of 2.65%. Emergent Biosolutions has a consensus price target of $12.00, indicating a potential upside of 42.01%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, analysts clearly believe Emergent Biosolutions is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Emergent Biosolutions beats OPKO Health on 10 of the 16 factors compared between the two stocks.

Get Emergent Biosolutions News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EBS vs. The Competition

Export

Metric	Emergent Biosolutions	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$440.12M	$3.62B	$6.84B	$23.30B
Dividend Yield	N/A	2.21%	2.66%	4.07%
P/E Ratio	-30.18	20.93	25.80	31.73
Price / Sales	0.59	344.83	544.00	111.69
Price / Cash	2.33	62.10	29.09	18.60
Price / Book	0.85	8.71	10.96	4.78
Net Income	$52.60M	$23.87M	$3.57B	$1.07B
7 Day Performance	5.62%	3.27%	2.49%	1.43%
1 Month Performance	-7.31%	1.50%	0.85%	0.75%
1 Year Performance	32.45%	68.98%	36.41%	25.24%

Emergent Biosolutions Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EBS Emergent Biosolutions	2.0277 of 5 stars	$8.45 -0.9%	$12.00 +42.0%	+33.2%	$440.12M	$742.90M	N/A	2,420	News Coverage
JNJ Johnson & Johnson	4.2229 of 5 stars	$231.12 +1.2%	$253.04 +9.5%	+69.4%	$549.78B	$94.19B	26.72	138,200	Trending News
NVAX Novavax	1.7609 of 5 stars	$9.00 -1.4%	$13.00 +44.4%	+46.9%	$1.50B	$1.12B	N/A	1,990
ZBIO Zenas BioPharma	3.6091 of 5 stars	$20.80 +5.2%	$44.29 +112.9%	+166.7%	$1.25B	$10M	N/A	N/A	Analyst Upgrade Gap Up
MNKD MannKind	2.9108 of 5 stars	$3.89 -1.3%	$8.97 +130.6%	+12.8%	$1.22B	$348.97M	N/A	400	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EBS) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, NVAX, ZBIO, MNKD, and OPK

How does Emergent Biosolutions compare to Johnson & Johnson?

Summary

How does Emergent Biosolutions compare to Novavax?

Summary

How does Emergent Biosolutions compare to Zenas BioPharma?

Summary

How does Emergent Biosolutions compare to MannKind?

Summary

How does Emergent Biosolutions compare to OPKO Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, NVAX, ZBIO, MNKD, and OPK

How does Emergent Biosolutions compare to Johnson & Johnson?

Does the media prefer JNJ or EBS?

Do institutionals & insiders hold more shares of JNJ or EBS?

Which has more volatility & risk, JNJ or EBS?

Is JNJ or EBS more profitable?

Which has better earnings & valuation, JNJ or EBS?

Do analysts rate JNJ or EBS?

Summary

How does Emergent Biosolutions compare to Novavax?

Which has preferable earnings & valuation, NVAX or EBS?

Which has more risk & volatility, NVAX or EBS?

Does the media favor NVAX or EBS?

Do institutionals and insiders hold more shares of NVAX or EBS?

Is NVAX or EBS more profitable?

Do analysts recommend NVAX or EBS?

Summary

How does Emergent Biosolutions compare to Zenas BioPharma?

Does the media prefer ZBIO or EBS?

Which has more volatility and risk, ZBIO or EBS?

Is ZBIO or EBS more profitable?

Do analysts prefer ZBIO or EBS?

Do insiders & institutionals have more ownership in ZBIO or EBS?

Which has preferable valuation & earnings, ZBIO or EBS?

Summary

How does Emergent Biosolutions compare to MannKind?

Does the media favor EBS or MNKD?

Is EBS or MNKD more profitable?

Which has more volatility and risk, EBS or MNKD?

Do analysts recommend EBS or MNKD?

Do institutionals & insiders believe in EBS or MNKD?

Which has better valuation and earnings, EBS or MNKD?

Summary

How does Emergent Biosolutions compare to OPKO Health?

Is OPK or EBS more profitable?

Do institutionals & insiders believe in OPK or EBS?

Which has higher earnings & valuation, OPK or EBS?

Which has more risk and volatility, OPK or EBS?

Does the media prefer OPK or EBS?

Do analysts recommend OPK or EBS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools